Customs at Cincinnati intercepts about 5,000 GLP-1 peptide shipments from China

Officers working at the Port of Cincinnati identified more than 300 "master carton" smuggling attempts from China between December 2025 and March 25, 2026, according to a Customs and Border Protection release dated March 31, 2026. Inside those cartons were about 5,000 individual, pre-labeled peptide shipments ^[1].

The intercepted products included semaglutide, tirzepatide, retatrutide, cagrilintide and other peptides, and the shipments were mis-manifested to hide what they contained ^[1].

The supply chain behind the seizures

For roughly two decades, chemistry suppliers in China — clustered in the Shenzhen, Hangzhou and Wuhan biotech corridors — have been the world's largest source of bulk peptides for research and pharmaceutical manufacturing ^[1]. When worldwide demand for GLP-1 drugs climbed sharply in 2023 and 2024, a share of that output was routed through reseller middlemen toward individual buyers in the United States, Britain, the European Union, Australia, India and other markets, according to a published review of the trade ^[1].

Those resellers usually package the peptide into small freeze-dried vials and mail them abroad; the buyer adds bacteriostatic water and injects the result ^[1]. One vial holding what would last two to three months at clinical doses typically sells for $40 to $100, against a US list price of $1,349 a month for branded Wegovy ^[1].

Enforcement has moved beyond the border

The Cincinnati intercepts sit inside a wider push described in the same review. In September 2025, the FDA set up an import alert that subjects GLP-1 active pharmaceutical ingredients from manufacturers not on its vetted list to detention without physical examination when they reach the border ^[1]. FDA Commissioner Makary announced a broader crackdown on GLP-1 API importation and marketing on February 6, 2026, and on February 20, 2026 the agency issued 30 warning letters in a single day to telehealth companies over how they marketed compounded GLP-1 products ^[1].

On April 1, 2026, a Utah osteopathic physician was federally indicted on allegations that he bought unapproved peptides from China through a middleman and sold them to more than 200 patients ^[1].

Globally, INTERPOL's Operation Pangea XVIII ran from March 10 to 23, 2026, with results announced May 7 and 8, 2026. It covered 90 countries and led to 269 arrests and the breakup of 66 criminal organizations; seized goods were valued at more than $15.5 million ^[1]. Testing turned up sibutramine — a weight-loss drug pulled from US and EU shelves in 2010 over heart risks — inside products sold as GLP-1 agonists. A separate raid on a Thai aesthetic clinic netted more than 300 vials of semaglutide and tirzepatide, though INTERPOL does not connect the sibutramine finding to that raid ^[1].

Why it matters for patients

Buying unapproved injectables for personal use is against the law in essentially every developed country covered by the review ^[1]. US law bars unapproved drugs from interstate commerce, and the FDA has said importing them for personal use is illegal even in small quantities; CBP seizes peptide mail at international mail facilities routinely ^[1]. Prosecutions of individual patients over a single vial are very rare, and suppliers and resellers carry far more legal risk. Even so, the review notes that rarely enforced is not the same as legal ^[1].

For someone who has already paid for a shipment, a seizure means the product never arrives. Whether buyers get their money back has not been reported.

Lab testing answers less than it appears to. A report can confirm identity, purity and how much drug is in a vial, but sterility and bacterial endotoxin need separate tests ^[1]. No laboratory publishes an overall failure rate for gray-market peptides, and samples are chosen by the buyers themselves, so there is no measured picture of what the market contains ^[1]. A good vial and a bad one look identical once the powder is mixed ^[1].

The review also points to a liability side that patients tend to underestimate: if a complication follows a self-administered unapproved injectable from an overseas source, treating doctors face a difficult position on continuing care, and hospital paperwork recording that detail can carry insurance and employment consequences ^[1].

What happens next

No CBP seizure figures for any period after March 25, 2026 have been reported, and the Utah case has not reached a disclosed outcome ^[1]. The specific measures behind the FDA's February 2026 importation crackdown have not been reported ^[1].